Meeting the Challenges of LGWP Propellants in MDI Redevelopment

As the medical and pharmaceutical industries work toward sustainability, a significant regulatory update is reshaping the development of Metered Dose Inhalers (MDIs), such as those used for asthma treatment. Traditional MDIs often rely on HFA (hydrofluoroalkane) propellants, which, while effective, have a high global warming potential. The shift to Low Global Warming Potential (LGWP) propellants represents an important step in reducing the environmental impact of these life-saving devices.

However, this change is not without its challenges. Many eco-friendly LGWP propellants tend to be highly flammable, adding complexity to the redevelopment process for MDIs. Ensuring product efficacy, maintaining regulatory compliance, and upholding laboratory safety standards are now top priorities for manufacturers navigating this transition.

The Role of Automation in Redevelopment

The redevelopment of MDIs to accommodate LGWP propellants is an intensive process, requiring precise testing and validation. Automation plays a critical role in meeting these demands efficiently and accurately. That’s where our Vertus® III, Vertus® III+, and DecaVertus® III automation products come in.

Designed specifically for Delivered Dose Uniformity (DDU) and Aerodynamic Particle Size Distribution (APSD) testing, these advanced automation solutions simplify and streamline the process of redevelopment and requalification of inhaler with LGWP propellants. Their ability to provide consistent and repeatable results makes them indispensable tools for idrug development.

Prioritizing Safety in the Laboratory

The flammability of LGWP propellants introduces new safety considerations for laboratories. Recognizing this, the design of the Vertus® III, Vertus® III+, and DecaVertus® III have been updated with an additional exhaust port to mitigate potential safety risks. This enhancement ensures effective venting of flammable gases, providing a safer working environment for users.

By addressing the unique challenges of LGWP propellants, these automation systems offer peace of mind, knowing both safety and performance are prioritized.

Supporting Sustainability Without Compromise

Transitioning to LGWP propellants is a necessary step toward sustainability, but it doesn’t have to come at the expense of efficiency or safety. With the right tools, manufacturers can confidently navigate this regulatory shift, ensuring their MDIs meet the highest environmental and safety standards while continuing to deliver reliable treatment options for patients.

If your laboratory is preparing for the shift to LGWP propellants, our Vertus®/DecaVertus® III solutions are here to support you. Together, we can meet the demands of a more sustainable future without compromising on quality or safety.